CTRI/2012/03/002473
Other
Phase 2
An open label study to evaluate the safety and efficacy of intranasal administration of LP011-09 versus Fluticasone propionate in subjects with allergic rhinitis
aila Pharmaceutical Pvt Ltd0 sites40 target enrollmentTBD
Overview
- Phase
- Phase 2
- Intervention
- Not specified
- Conditions
- Health Condition 1: null- Positive history of Allergic Rhinitis as judged by the Investigator
- Sponsor
- aila Pharmaceutical Pvt Ltd
- Enrollment
- 40
- Status
- Other
- Last Updated
- 4 years ago
Overview
Brief Summary
No summary available.
Investigators
Eligibility Criteria
Inclusion Criteria
- •Males or Female subjects in the age group of 18 to 65 years
- •Subject has a medical history and past treatment of Allergic rhinitis (Written or verbal confirmation) which includes Seasonal or perennial symptoms (Nasal Congestion, Rhinnothea, Nasal itching and Sneezing, Ocular redness, Ocular itching, Ocular Tearing, Ocular burning, Ocular swelling)
- •Subject has 6 or more in the mean reflective total nasal symptoms (rTNSS) score in which nasal congestion accounts for 1 or more during last 2 days from screening visit.
- •Women with child\-bearing potential \& planning a pregnancy should be excluded or if otherwise, willing to adopt effective and approved birth control regimen for the entire trial duration (oral contraceptive, intrauterine device, barrier plus spermicide).
- •Subject has no clinically significant abnormal findings on the physical examination with the exception of head, ears, eyes, nose and throat findings consistent with allergic rhinitis, medical history which in the opinion of the Investigator would jeopardise the safety of the subjects or impact the validity of the study results
- •Subjects who are willing to complete all the study procedure and willing to adhere to the study protocol
- •The ability to understand and sign an informed consent form
Exclusion Criteria
- •Female Subjects who are pregnant or lactating
- •Subject having complicated asthma which may require corticosteroids
- •Subject undergoing immunotherapy or has started the same in 1 month before the screening visit
- •Subject having complicated nasal disorders which may affect study efficacy (Acute or chronic rhinitis, hypertropic Rhinitis, Sinusitis, Septal Deviation, Nasal Polyp, Adenoid, and upper respiratory tract inflammation)
- •Subject having history of vasomotor rhinitis or eosonophilic rhinitis
- •Subject has serious (requiring Hospitalisation or surgery is indicated) hepatic disorder, renal disorder, heart disease, haematological disease, marrow disease and mental disease
- •Subject having acute , symptomatic respiratory tract infection within 2 weeks before screening
- •Subject has history of drug hypersensitivity
- •Subject has participated in another trial within 1 month prior to screening
- •Subject taking any anti\-allergy medication that in the opinion of the investigator will affect the study assessment
Outcomes
Primary Outcomes
Not specified
Similar Trials
Completed
Phase 4
An open label study to evaluate the safety and efficacy of Aclasta (Zoledronic acid) in treatment of patients with Glucocorticoid induced OsteoporosisCTRI/2010/091/000637ovartis Healthcare Pvt Limited60
Active, not recruiting
Phase 1
A study to evaluate the safety and effect of CFZ533 on patients with Graves’ diseaseGraves' diseaseMedDRA version: 19.0Level: LLTClassification code 10018706Term: Graves' diseaseSystem Organ Class: 100000004860Therapeutic area: Diseases [C] - Hormonal diseases [C19]EUCTR2015-005564-41-DEovartis Pharma Services AG15
Active, not recruiting
Phase 1
An open-label study to evaluate the safety and efficacy of IMATINIB with chemotherapy in pediatric patients with Ph+/BCR-ABL+ acute lymphoblastic leukemia (Ph+ALL)Children and adolescents aged 1-17 years at diagnosis, with Ph+ALLMedDRA version: 14.1Level: LLTClassification code 10000844Term: Acute lymphoblastic leukaemiaSystem Organ Class: 100000004864Therapeutic area: Diseases [C] - Cancer [C04]EUCTR2004-001647-30-ITA.I.E.O.P. - ASSOCIAZIONE ITALIANA EMATOLOGIA ONCOLOGIA PEDIATRICA550
Completed
Not Applicable
A clinical study to test the safety and the efficacy of a single-pill combination of 2 antihypertensive and 1 lipid-lowering drug in patients already well treated with the concomitant administration of the same three drugs on separate tabletsHypertension and dyslipidemiaCirculatory SystemISRCTN27159806Institut de Recherche Internationales Servier130
Active, not recruiting
Not Applicable
Open label study to evaluate effect, safety and tolerability of Betaferon standard dose of 250µg in patients of Chinese origin with multiple sclerosisEUCTR2014-004613-93-Outside-EU/EEABayer HealthCare AG35